If you have been reading about PTMA gene and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-11. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
=== Synthesis of urea === Although not usually isolated as such, the salt ammonium carbamate is produced on a large scale as an intermediate in the production of the commodity chemical urea from ammonia and carbon dioxide.
== Automation of the process == Structure determination by NMR has traditionally been a time-consuming process, requiring interactive analysis of the data by a highly trained scientist. There has been considerable interest in automating the process to increase the throughput of structure determination and to make protein NMR accessible to non-experts (See structural genomics). The two most time-consuming processes involved are the sequence-specific resonance assignment (backbone and side-chain assignment) and the NOE assignment tasks. Several different computer programs have been published that target individual parts of the overall NMR structure determination process in an automated fashion. Most progress has been achieved for the task of automated NOE assignment. So far, only the FLYA and the UNIO approach were proposed to perform the entire protein NMR structure determination process in an automated manner without any human intervention. Modules in the NMRFAM-SPARKY such as APES (two-letter-code: ae), I-PINE/PINE-SPARKY (two-letter-code: ep; I-PINE web server) and PONDEROSA (two-letter-code: c3, up; PONDEROSA web server) are integrated so that it offers full automation with visual verification capability in each step. Efforts have also been made to standardize the structure calculation protocol to make it quicker and more amenable to automation. Recently, the POKY suite, the successor of programs mentioned above, has been released to provide modern GUI tools and AI/ML features.
With the development of high-efficiency and high-power LEDs, it has become possible to use LEDs in lighting and illumination. To encourage the shift to LED lamps and other high-efficiency lighting, in 2008 the US Department of Energy created the L Prize competition. The Philips Lighting North America LED bulb won the first competition on August 3, 2011, after successfully completing 18 months of intensive field, lab, and product testing. Efficient lighting is needed for sustainable architecture. As of 2011, some LED bulbs provide up to 150 lm/W and even inexpensive low-end models typically exceed 50 lm/W, so that a 6-watt LED could achieve the same results as a standard 40-watt incandescent bulb. The lower heat output of LEDs also reduces demand on air conditioning systems. Worldwide, LEDs are rapidly adopted to displace less effective sources such as incandescent lamps and CFLs and reduce electrical energy consumption and its associated emissions. Solar powered LEDs are used as street lights and in architectural lighting. The mechanical robustness and long lifetime are used in automotive lighting on cars, motorcycles, and bicycle lights. LED street lights are employed on poles and in parking garages. In 2007, the Italian village of Torraca was the first place to convert its street lighting to LEDs. Cabin lighting on recent Airbus and Boeing jetliners uses LED lighting. LEDs are also being used in airport and heliport lighting.
==== Dame Commander of the Order of the British Empire (DBE) ==== Civil Dr Margaret Ebunoluwa Aderin, , Chancellor, University of Leicester. For services to Science Education and to Diversity. Amanda Jayne Blanc, Group Chief Executive Officer, Aviva. For services to Business, to Gender Equality and to Net-Zero. Professor Sonia Boyce, , Artist. For services to Art. Jilly Cooper, , Author. For services to Literature and to Charity. Felicity Ann Dahl, Founder, Roald Dahl's Marvellous Children's Charity and the Roald Dahl Museum and Story Centre. For services to Philanthropy, to Literature and to Young People. Dr Jennifer Dixon, , Chief Executive, The Health Foundation. For services to the NHS and to Public Health. Tristina Adele Harrison, Chief Executive Officer, TalkTalk Group. For services to Telecommunications. Dianne Michèle Jeffrey, , lately Trustee and Founder Chair, Age International. For services to Older People Abroad and to the community in Derbyshire. Professor Valerie Joan Lund, , Emeritus Professor in Rhinology, University College London. For services to Rhinology. Siobhain Ann McDonagh, , Member of Parliament for Mitcham and Morden. For Parliamentary and Political Service. Ruth Elizabeth Miskin, , Children's Reading Expert, Read Write Inc. For services to Education. Marit Mohn, Philanthropist. For services to Philanthropy. Professor Molly Morag Stevens, , John Black Professor of Bionanoscience, University of Oxford and Professor, Imperial College London. For services to Medicine.
Sources: en.wikipedia.org
Truck terminals in proximity to industrial clusters, machinery and manufacturing units, agro-processing zones, and integrated cold-chain storage facilities will be planned to build the export-ready and quick logistics infrastructure. The HHBTMSM Expressway will have a separate provision for the optical fiber connectivity and gas pipelines, turning the greenfield expressway into a 'digital-ready' utility corridor.
=== Czech Republic === After joining NATO, the Army of the Czech Republic developed a combat ration known as the BDP (Czech: Bojová Dávka Potravin). The BDP comes in two versions, type I and II, each holding two ready-to-eat main courses packed in large foil "cans" (beef roast with rice, pork goulash with potato, spicy risotto, pork with carrots and vegetables, etc.), a small plastic cup of lunch meat spread, cheese spread, hard bread, cookies, jam, instant coffee, tea bags, fruit-flavored multivitamin drink tablets, vitamin C enriched fruit drink powder, a chocolate bar, sugar, salt, chewing gum, wet napkins, paper towels, a plastic bag, and a menu and instruction sheet. A modified version of the BDP known as the KDP (Czech: Konzervovaná Dávka Potravin) is also used. This contains the same items as the BDP, but adds an aluminium cup, plastic utensils, a folding stove with fuel tablets and matches, and soap.
== Specific varieties == Tripolite is the variety found in Tripoli, Libya. Bann clay is the variety found in the Lower Bann valley in Northern Ireland. Moler (mo-clay) is the variety found in northwestern Denmark, especially on the islands of Fur and Mors. Freshwater-derived food grade diatomaceous earth is the type used in United States agriculture for grain storage, as feed supplement, and as an insecticide. It is produced uncalcinated, has a very fine particle size, and is very low in crystal silica (<2%). Salt-water-derived pool / beer / wine filter grade is not suitable for human consumption or effective as an insecticide. Usually calcinated before being sold to remove impurities and undesirable volatile contents, it is composed of larger particles than the freshwater version and has a high crystalline silica content (>60%).
=== Discovery === In 1869, while studying the structure of the pancreas under a microscope, Paul Langerhans, a medical student in Berlin, identified some previously unnoticed tissue clumps scattered throughout the bulk of the pancreas. The function of the "little heaps of cells", later known as the islets of Langerhans, initially remained unknown, but Édouard Laguesse later suggested they might produce secretions that play a regulatory role in digestion. Paul Langerhans' son, Archibald, also helped to understand this regulatory role. In 1889, the physician Oskar Minkowski, in collaboration with Joseph von Mering, removed the pancreas from a healthy dog to test its assumed role in digestion. On testing the urine, they found sugar, establishing for the first time a relationship between the pancreas and diabetes. In 1901, another major step was taken by the American physician and scientist Eugene Lindsay Opie, when he isolated the role of the pancreas to the islets of Langerhans: "Diabetes mellitus when the result of a lesion of the pancreas is caused by destruction of the islets of Langerhans and occurs only when these bodies are in part or wholly destroyed". Over the next two decades researchers made several attempts to isolate the islets' secretions. In 1906, George Ludwig Zuelzer achieved partial success in treating dogs with pancreatic extract, but he was unable to continue his work. Between 1911 and 1912, E.L.
The common adverse effects of bupropion with the greatest difference from placebo are dry mouth, nausea, constipation, insomnia, anxiety, tremor, and excessive sweating. Bupropion has the highest incidence of insomnia of all second-generation antidepressants, apart from desvenlafaxine. It is also associated with about 20% increased risk of headache. Bupropion raises blood pressure in some people. One study showed an average rise of 6 mm Hg in systolic blood pressure in 10% of patients. The prescribing information notes that hypertension, sometimes severe, is observed in some people taking bupropion, both with and without pre-existing hypertension. The safety of bupropion in people with cardiovascular conditions and its general cardiovascular safety profile remains unclear due to the lack of data. Bupropion has not been associated with QT prolongation at therapeutic doses but has been associated with QT prolongation in overdose. Seizure is a rare but serious adverse effect of bupropion. It is strongly dose-dependent: for the immediate release preparation, the seizure incidence is 0.4% at 300 to 450 mg per day; the incidence climbs almost 10-fold for the higher-than-recommended dose of 600 mg. For comparison, the incidence of unprovoked seizure in the general population is 0.07 to 0.09%, and the risk of seizure for a variety of other antidepressants is generally 0 to 0.5% at the recommended doses. Rare cases of liver toxicity leading to death or liver transplantation have been reported for bupropion.
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.